SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

10 Aug 2023 Evaluate
The June 2023 quarter revenue stood at Rs. 495.88 millions, up 10.33% as compared to Rs. 449.44 millions during the corresponding quarter last year.The Company's Net profit for the June 2023 quarter have declined marginally to Rs. 177.21  millions as against Rs. 177.71 millions reported during the corresponding quarter ended.Operating Profit saw a handsome growth to 245.81 millions from 242.02 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 495.88 449.44 10.33 495.88 449.44 10.33 1489.73 1148.54 29.71
Other Income 10.75 14.23 -24.46 10.75 14.23 -24.46 60.24 40.50 48.74
PBIDT 245.81 242.02 1.57 245.81 242.02 1.57 802.42 620.96 29.22
Interest 0.25 0.62 -59.68 0.25 0.62 -59.68 2.01 8.28 -75.72
PBDT 245.56 241.40 1.72 245.56 241.40 1.72 800.41 612.68 30.64
Depreciation 7.49 5.70 31.40 7.49 5.70 31.40 25.76 22.33 15.36
PBT 238.07 235.70 1.01 238.07 235.70 1.01 774.65 590.35 31.22
TAX 60.86 57.99 4.95 60.86 57.99 4.95 194.96 154.10 26.52
Deferred Tax 0.96 -1.92 -150.00 0.96 -1.92 -150.00 2.55 0.72 254.17
PAT 177.21 177.71 -0.28 177.21 177.71 -0.28 579.69 436.25 32.88
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 49.57 53.85 -7.95 49.57 53.85 -7.95 53.86 54.07 -0.37

Guj. Themis Biosyn Share Price

330.15 10.70 (3.35%)
20-Apr-2026 14:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×